|Articles|May 15, 2019
- Pharmaceutical Technology-05-15-2019
- Volume 2019 eBook
- Issue 1
The Link Between Manufacturing and Commercialization in Gene and Cell Therapies
The highly customized nature of cell and gene therapy production means that manufacturing innovations for one therapy may not be easily transferable to others.
Advertisement
Now that the first cell and gene therapies have become commercial realities and more companies are involved in precision medicine research, different manufacturing platforms are being developed. However, as the authors write, developers need to consider the fundamental differences between these therapies and more traditional biopharmaceuticals to develop the right commercialization strategies.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing 2019
May 2019
Pages: 30–35
Citation
When referring to this article, please cite it as W. Colasante, P. Diesel, and L. Gerlovin, “The Link Between Manufacturing and Commercialization in Gene and Cell Therapies," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2019).
Articles in this issue
over 6 years ago
Supply Chain Challenges for Single-Use Systemsover 6 years ago
Challenges with Successful Commercialization of Biosimilarsover 6 years ago
Test Methods and Quality Control for Prefilled Syringesover 6 years ago
Unknown and Unknowableover 6 years ago
Distinguishing Between Cleanroom Classification and MonitoringNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
